Moderna ($MRNA) falls even after “good news”: 2025 sales tracking above guidance, cost cuts reiterated, and 2026 growth outlook held steadyWhat happenedModerna told investors at the J.P. Morgan Healthcare Conference that 2025 revenue should be about $1.9B (above the midpoint of prior guidance). It reiterated a plan for up to 10% revenue growth in 2026 and guided to 2026 non-adjusted operating expenses of about $4.9B (down from an estimated $5.0B–$5.2B in 2025). Despite that, the stock fell as the market stayed focused on the path to cash breakeven and whether costs need to come down faster. It also said it has filed for approval of its standalone seasonal flu vaccine (mRNA-1010) in multiple countries, with potential approvals beginning in 2026.Why the market caresThis is a “trust and timeline” story: investors want proof that Moderna can grow beyond COVID and get to breakeven without repeated resets. Any hint that growth is capped (or that spending cuts aren’t deep enough) can pressure the entire high-multiple biotech space.Winners1. Large-cap pharma with vaccine scale and respiratory franchisesModerna’s update reinforces that the respiratory vaccine market is stabilising into a more “normal” commercial rhythm (seasonal demand + portfolio management). Bigger platforms with diversified cash flows can benefit if the market shifts from hype to execution (distribution, pricing discipline, combo-product roadmaps).Names: $MRK (Merck & Co.), $PFE (Pfizer), $GSK (GSK plc)2. Bioprocessing and life-science tools tied to biologics manufacturing efficiency When vaccine makers pivot to cost control, they often optimise supply chains and standardise production—still requiring high-volume consumables, bioprocess hardware, and QC workflows. If Moderna (and peers) keep advancing late-stage pipelines while tightening opex, the “sell the picks and shovels” cohort can hold up better than single-asset biotechs.Names: $TMO (Thermo Fisher Scientific), $DHR (Danaher), $AVTR (Avantor)3. Immuno-oncology leaders that can gain from positive read-through on cancer vaccine dataModerna has highlighted meaningful 2026 clinical readouts, including its personalised cancer vaccine work with Merck. If upcoming data are constructive, sentiment can lift across immuno-oncology and combination-therapy ecosystems, not just Moderna.Names: $BMY (Bristol Myers Squibb), $REGN (Regeneron Pharmaceuticals), $MRK (Merck & Co.)Losers1. Cash-burn, funding-sensitive biotechWhen a high-profile biotech gets punished even after reaffirming guidance, it’s a reminder that markets are prioritising capital discipline. That often tightens risk appetite for companies that rely on future raises and don’t have near-term revenue visibility.Names: $SANA (Sana Biotechnology), $VIR (Vir Biotechnology), $BEAM (Beam Therapeutics)2. COVID-era vaccine “pure plays” and smaller vaccine developers with choppier demand outlooksModerna’s revenue level (far below pandemic peaks) underscores how competitive and demand-sensitive the post-COVID vaccine landscape remains. Smaller players can be more exposed to seasonal volatility, pricing pressure, and channel dynamics.Names: $NVAX (Novavax), $OCGN (Ocugen)3. Retail pharmacy chains exposed to softer vaccination traffic versus prior yearsEven with “less-bad-than-feared” trends, US retail vaccination volumes have been under pressure. If respiratory season traffic doesn’t rebound strongly, it can weigh on high-frequency front-of-store economics and service-margin expectations. Names: $CVS (CVS Health), $WBA (Walgreens Boots Alliance)#StockMarket #Trading #Investing #DayTrading #SwingTrading #Biotech #Vaccines #Pharma #Earnings #Healthcare #mRNA #USStocks #OptionsTrading #MarketNews

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.